Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jolene M. Kriett is active.

Publication


Featured researches published by Jolene M. Kriett.


The Annals of Thoracic Surgery | 1995

Primary pulmonary artery sarcoma: A report of six cases

Mark B. Anderson; Jolene M. Kriett; David P. Kapelanski; Riyad Y. Tarazi; Stuart W. Jamieson

Pulmonary artery tumors are rare and a frequently overlooked cause of pulmonary artery occlusion. The presentation is one of progressive pulmonary dysfunction and right ventricular failure. The diagnosis seldom is made preoperatively. We report 6 cases of primary sarcoma of the pulmonary artery identified at operation, which were treated surgically. Resection with or without adjuvant therapy currently offers the only chance for survival. Emphasis must be placed on earlier identification of these tumors.


American Journal of Cardiology | 1999

Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension

Abraham Rothman; Mark S. Sklansky; Victor Lucas; Iraj A. Kashani; Robin D. Shaughnessy; Richard N. Channick; William R. Auger; Peter F. Fedullo; Cecelia M Smith; Jolene M. Kriett; Stuart W. Jamieson

Long waiting times for lung transplantation have limited the survival of patients with advanced pulmonary hypertension. Atrial septostomy has been used in this group of patients in an attempt to prolong survival. We evaluated the results of atrial septostomy in 12 patients using the static graded balloon dilation technique. Between December 1990 and May 1998, 10 women and 2 men (ages 13 to 56 years, mean 37 years) underwent atrial septostomy. Nine patients had primary and 3 patents had secondary pulmonary hypertension. Five patients deteriorated despite long-term intravenous prostacyclin infusions. The atrial septum was crossed with a Brockenbrough needle, followed by an 0.035-J exchange wire and progressively larger catheter balloons for atrial septal dilation, until systemic oxygen saturation decreased 5% to 10%. An atrial septal defect was successfully created in each patient. The mean right atrial pressure decreased from 23 to 18 mm Hg and the mean systemic oxygen saturation decreased from 93% to 85%. The mean cardiac index increased from 1.7 to 2.1 L/min/m2 and the mean systemic oxygen transport increased from 268 to 317 ml/min/m2. Complications occurred in 3 patients: transient hypotension during transesophageal echocardiography, a femoral pseudoaneurysm, and a femoral arteriovenous fistula. After septostomy, 6 patients had clinical improvement (resolution of ascites, edema, and no further episodes of syncope); 5 of these 6 patients underwent lung transplantation a mean of 6.1 months after septostomy. Six patients did not have clinical improvement after septostomy. Atrial septostomy improves the hemodynamic status and may be useful as a bridge to lung transplantation in selected patients with pulmonary hypertension.


Journal of the American College of Cardiology | 1983

Prevention of recurrent sudden cardiac arrest: role of provocative electropharmacologic testing

David G. Benditt; D. Woodrow Benson; George J. Klein; Marc Pritzker; Jolene M. Kriett; Robert Anderson

This study evaluates the usefulness of serial provocative electropharmacologic testing for predicting the efficacy of prophylactic antiarrhythmic treatment regimens in patients resuscitated from sudden cardiac arrest in the absence of acute myocardial infarction. Testing was carried out in 34 consecutive patients (28 men and 6 women) who required cardiopulmonary resuscitation and direct current countershock for treatment of primary ventricular fibrillation (28 patients), ventricular tachycardia (5 patients) or excessively rapid heart rate during atrial fibrillation with preexcitation (1 patient). In 8 (24%) of the 34 patients, drug testing either was not feasible because of absence of inducible arrhythmia or was incomplete because of patient withdrawal from study; and 3 of these 8 patients had recurrent sudden cardiac arrest within 10 to 19 months. In an additional five patients, treatment regimens failed to prevent initiation of sustained ventricular tachyarrhythmias in the catheterization laboratory, and two of these five patients had cardiac arrest recurrences within 2 weeks to 25 months of follow-up. In the remaining 21 (62%) of the 34 patients, including 3 patients with preexcitation syndrome, a drug regimen or surgical treatment, or both, was found that prevented inducible life-threatening tachyarrhythmias in the laboratory. Subsequently, only 1 (5%) of these 21 patients died suddenly within a 7 to 38 month (mean +/- standard deviation, 18 +/- 8.3) follow-up period. Thus, provocative electropharmacologic testing appears to be useful in predicting response to therapy in survivors of sudden cardiac arrest.


The Annals of Thoracic Surgery | 2002

Donor transfer of pulmonary coccidioidomycosis in lung transplantation

Uttam Tripathy; Gordon L. Yung; Jolene M. Kriett; Patricia A. Thistlethwaite; David P. Kapelanski; Stuart W. Jamieson

Transplant recipients living in endemic areas are at high risk of aerosol-transmitted fungal infections because of environmental exposure while on immunosuppressive drugs, as well as reactivation of latent infection from either the patients or the donors organs. The latter may account for early development of coccidioidomycosis after transplantation. We describe a case of pulmonary coccidioidomycosis in a lung transplant recipient who acquired the infection from the donor lung and presented with fulminant pneumonia in the immediate postoperative period.


Transplantation | 1993

Primary diagnosis predicts prognosis of lung transplant candidates

Ann M. Hayden; Rebecca C. Robert; Jolene M. Kriett; Cecilia M. Smith; Kieran Nicholson; Stuart W. Jamieson

Optimal timing for consideration of lung transplantation remains unknown. This study examined survival in patients with end-stage lung disease awaiting transplantation. Primary disease group and relevant indicators were evaluated. Ninety-three patients who met selection criteria for lung transplantation were included in this retrospective review. Of this total, 31% underwent transplantation, 38% remain waiting, and 31% died. Results demonstrate that the six-month actuarial survival rate was 89% for Eisenmengers syndrome, 81% for emphysema, 74% for cystic fibrosis, 60% for primary pulmonary hypertension, and 38% for interstitial lung disease. Parameters found to be significant included a higher mean right atrial pressure in primary pulmonary hypertension patients who died awaiting transplantation, and lower forced expiratory volume in one second and forced vital capacity measurements in cystic fibrosis patients who died awaiting transplantation. We conclude that primary disease significantly affects survival in candidates awaiting transplantation. Reliable indicators predictive of survival are not available. Earlier referral for consideration of lung transplantation is recommended.


The Journal of Thoracic and Cardiovascular Surgery | 1996

Volume reduction of the native lung after single-lung transplantation for emphysema

David P. Kapelanski; Mark B. Anderson; Jolene M. Kriett; Henri G. Colt; Cecilia M. Smith; Manuel Mateos; Stuart W. Jamieson

Emphysema is currently the most frequent indication for single-lung transplantation. A decade ago, however, it was postulated that after single-lung transplantation the emphysematous contralateral lung would be preferentially ventilated, with consequent mediastinal shift and compression of the graft. Conversely, the attenuated capillary bed of the diseased lung would necessitate preferential perfusion of the graft. 1 The theoretic prospect of wholesale ventilation-perfusion mismatch has not been a significant concern in clinical practice, and during this period the combination of ongoing restrictions in the donor pool, the accumulation of excellent functional outcomes after unilateral transplantation, and the higher operative morbidity associated with bilateral procedures has compelled increasing use of single-lung transplantation for the management of end-stage emphysema. Because graft function is the preeminent factor when pulmonary mechanics and gas exchange are assessed at successively remote intervals after single-lung transplantation, the fate of the retained native lung has not been well summarized, and we are unaware of any series describing the discrete effects of the residual emphysematous lung on pulmonary allograft function. We present a case of progressive pulmonary dysfunction associated with marked hyperinflation of the native lung in a single-lung recipient, with successful management by a unilateral volume-reduction operation. One of us (M. M.) underwent a right single-lung transplant for emphysema in 1991, and after an uneventful postoperative course was able to resume his medical practice. Within 3 years, however, dyspnea and exercise intolerance recurred. There was no improvement despite treatment of a concurrent infection, and empirical augmentation of the immunosuppressive regimen afforded only transient relief. Supplemental oxygen was administered at rest and during exercise. The chest radiograph demonstrated marked hyperinflation of the native lung, with mediastinal displacement and depression of the left hemidiaphragm (Fig. 1, A). Consecutive pulmonary function studies documented serial reductions in expiratory flow and vital capacity while residual volume and functional residual capacity were concurrently expanding (Table I). Volume reduction of the native lung was proposed as an alternative to retransplantation.


Journal of Heart and Lung Transplantation | 2001

Outpatient inhaled nitric oxide in a patient with idiopathic pulmonary fibrosis: a bridge to lung transplantation ☆

Gordon L. Yung; Jolene M. Kriett; Stuart W. Jamieson; F. Wayne Johnson; John W. Newhart; Katie Kinninger; Richard N. Channick

Inhaled nitric oxide (INO) has been shown to improve oxygenation and decrease intrapulmonary shunt and pulmonary hypertension in various lung diseases. In this study we report a patient with end-stage idiopathic pulmonary fibrosis and pulmonary hypertension who received INO after coronary artery bypass surgery, with significant improvement in arterial oxygenation and pulmonary arterial pressure. Using a pulsing delivery system, the patient continued to receive outpatient INO for 30 months while waiting for lung transplantation. Exercise study and two-dimensional echocardiogram, after 3 months of inhaled NO, demonstrated continued benefits of INO for improvement of arterial oxygenation, pulmonary arterial pressure and exercise tolerance.


Journal of Cardiothoracic and Vascular Anesthesia | 1992

Airway management during anesthesia for double-lung transplantation using a single-lumen endotracheal tube with an enclosed bronchial blocker

Mark S. Scheller; Jolene M. Kriett; Cecilia M. Smith; Stuart W. Jamieson

Abstract The approach to airway management in patients undergoing lung transplantation is dependent on the type of transplant procedure (combined heart-lung, single-lung, or double-lung technique), the site of the airway anastomosis (trachea or mainstem bronchus), and whether cardiopulmonary bypass (CPB) will be used. Modifications of the original operative technique for double-lung transplantation 1,2 have been introduced recently including the use of bilateral bronchial anastomoses 3 and sequential single-lung transplantation. 4 The respective advantages of these techniques include the improved collateral blood supply at the donor bronchial anastomosic sites, thereby decreasing the risk of ischemic airway complications, and the potential elimination of the need for CPB. Specific strategies for airway management during double-lung transplantation have not been previously addressed. This report describes recent experience with a patient who underwent double-lung transplantation without CPB using a single-lumen endotracheal tube with enclosed bronchial blocker (Univent tube, Fuji Systems Corporation, Tokyo, Japan).


The Annals of Thoracic Surgery | 1997

Surgical management of ventricular tachycardia.

Sara J. Shumway; Eric Johnson; Charles Svendsen; Jolene M. Kriett; W. Steves Ring

BACKGROUND Ventricular tachyarrhythmias are the leading cause of death from coronary artery disease. A small percentage of these arrhythmias originate in chronically ischemic myocardium, rather than acutely ischemic myocardium, and can be refractory to medical management. Epicardial mapping and focal cryoablation of foci demonstrating early activation may provide definitive therapy when pharmacologic management fails. We report a series of 42 consecutive patients with refractory ventricular tachycardia (VT) who were treated with open epicardial mapping and focal cryoablation after pharmacologic management failed. METHODS We retrospectively reviewed the records of patients who underwent surgical treatment of malignant VT. For patients not recently seen in the clinic, we conducted telephone interviews. At the time of operation, epicardial mapping was performed to locate foci of early electrical activation. These foci were then cryoablated, using 2-minute applications of liquid nitrogen-cooled probes. All patients underwent postoperative electrophysiologic studies to test for inducible VT. RESULTS Of these 42 patients, 34 (81%) were male, 8 (19%) female. Average age was 62.9 +/- 10.6 years; ejection fraction, 0.20 (range, 0.04 to 0.50); and number of foci ablated, 2.1 +/- 1.1 (range, 1 to 6). At the time of cryoablation, all patients underwent additional procedures, including aneurysmectomy, coronary artery bypass, or valve replacement. The 30-day operative mortality was 9.5% (4 of 42). Of the 38 survivors, 36 (94.7%) were clinically free of VT; the remaining 2 had spontaneous or inducible VT. CONCLUSIONS Open cryoablation of foci propagating VT appears to be safe and effective. It may be the most definitive treatment for malignant VT.


Circulation | 1984

Enhanced atrioventricular nodal conduction in man: electrophysiologic effects of pharmacologic autonomic blockade.

D. G. Benditt; G. J. Klein; Jolene M. Kriett; Ann Dunnigan; D. W. Benson

Enhanced atrioventricular nodal conduction (EAVC) comprises a portion of the spectrum of atrioventricular node electrophysiology in which physiologic slowing of atrioventricular conduction is diminished. To evaluate the basis of EAVC in humans, we compared the effect of pharmacologic autonomic blockade on electrophysiologic characteristics of atrioventricular nodal conduction and refractoriness in 10 patients with EAVC and 12 patients without EAVC (non-EAVC). The effects of autonomic blockade (0.2 mg/kg iv propranolol and 0.04 mg/kg iv atropine) on sinus cycle length and atrial refractory period were similar in both EAVC and non-EAVC patients. After autonomic blockade, minimum atrial paced cycle length with 1:1 atrioventricular conduction lengthened in EAVC patients (control, 268 +/- 25 msec; blockade, 307 +/- 34 msec; p less than .01), but remained unchanged in non-EAVC patients (control, 392 +/- 69 msec; blockade, 382 +/- 49 msec; p = NS). Similarly, atrioventricular nodal functional refractory periods tended to lengthen in EAVC patients, while remaining unchanged or shortening in non-EAVC patients. Furthermore, although autonomic blockade reduced differences between EAVC and non-EAVC patients, both minimum cycle length with 1:1 atrioventricular conduction and atrioventricular functional refractory period remained shorter in EAVC than in non-EAVC patients (p less than .02). Thus, baseline differences in autonomic atrioventricular nodal control differ in EAVC and non-EAVC patients, but do not fully account for differences in atrioventricular nodal electrophysiologic properties in these patients. Consequently, underlying structural functional factors may play an important role in determining the range of atrioventricular nodal electrophysiologic characteristics in man.

Collaboration


Dive into the Jolene M. Kriett's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gordon L. Yung

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge